SAN
DIEGO, March 3, 2022 /PRNewswire/ -- Cue Health
Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today
announced that it is further collaborating with the University of Pittsburgh Medical Center Children's
Community Pediatrics ("UPMC CCP"), part of UPMC Children's Hospital
of Pittsburgh, Pennsylvania. Cue
will expand its distribution of Cue's Health Monitoring Systems and
Cue COVID-19 tests to additional pediatric clinics to support
testing for even more patients, physicians, nurses, and
staff.
With over 55 locations and more than 250 pediatric providers
throughout western and central Pennsylvania, UPMC CCP offers standard well
and sick care, as well as a variety of specialty services. With
this expansion, Cue's tests will be integrated in several clinics
as part of UPMC CCP's care and treatment.
Cue's test uses molecular nucleic acid amplification technology
(NAAT) and is the most accurate* self-test for COVID-19, providing
lab-quality results directly to connected mobile devices in 20
minutes. The test is able to detect all known COVID-19 variants of
concern, including Omicron, and can be used on adults and children
(age 2 years and over for OTC/home use and under 2 years for
professional use), with or without symptoms.
"Cue's adaptable testing platform has served the UPMC community
for the last six months, and we are thrilled to extend our
relationship with the company to provide much-needed COVID-19
testing to even more children and families in Pittsburgh. We're grateful to Cue's alignment
with our mission of providing outstanding patient care and shaping
the health system of tomorrow," said John
Wedge, Senior Category Manager from UPMC.
"UPMC Children's Hospital of Pittsburgh is renowned for its world-class
care and dedication to improving the health and well-being of
children, and we are proud to support them on their critically
important mission," said Ayub
Khattak, Co-founder and CEO of Cue Health.
UPMC Children's Community Pediatrics is one of several
healthcare-affiliated organizations to which Cue provides its
tests, including internationally recognized hospital systems
throughout the U.S. Cue also provides tests to Google, the National
Basketball Association, and Major League Baseball, among other
organizations.
About Cue Health
Cue Health (Nasdaq: HLTH) is a
healthcare technology company that makes it easy for individuals to
access health information and places diagnostic information at the
center of care. Cue Health enables people to manage their health
through real-time, actionable, and connected health information,
offering individuals and their healthcare providers easy access to
lab-quality diagnostics anywhere, anytime, in a device that fits in
the palm of the hand. Cue Health's first-of-its-kind COVID-19 test
was the first FDA-authorized molecular diagnostic test for at-home
and over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, regulatory
approval from India's Central
Drugs Standard Control Organization, and PSAR authorization from
Singapore's Health Sciences
Authority. Cue was founded in 2010 and is headquartered in
San Diego. For more information,
please visit www.cuehealth.com.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements". The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including those related
to the expected future diagnostic test menu and the factors
discussed in the "Risk Factors" section of the Form 10-Q dated
November 10, 2021 filed by Cue with
the SEC. Any forward-looking statements contained in this press
release are based on the current expectations of Cue's management
team and speak only as of the date hereof, and Cue specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
These products have not been FDA cleared or approved; but
have been authorized by FDA under an Emergency Use Authorization
(EUA). These products have been authorized only for the detection
of nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens. The emergency use of these products is only authorized
for the duration of the declaration that circumstances exist
justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
*Based on clinical study results submitted to FDA for other
EUA molecular home tests.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cue-health-expands-collaboration-with-upmc-childrens-community-pediatrics-to-bring-highly-accurate-molecular-testing-to-an-expanded-network-of-clinics-301494519.html
SOURCE Cue Health Inc.